Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes

INTRODUCTION: Sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors ameliorate blood glucose levels in patients with type 2 diabetes mellitus (T2DM) by inhibiting the reabsorption of glucose from the kidneys, thus increasing urinary glucose excretion. Most SGLT2 inhibitors have been reported t...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumura, Takeshi, Makabe, Tomoko, Ueda, Seiko, Fujimoto, Yuki, Sadahiro, Kayo, Tsuruyama, Shiori, Ookubo, Yuma, Kondo, Tatsuya, Araki, Eiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399319/
https://www.ncbi.nlm.nih.gov/pubmed/35840857
http://dx.doi.org/10.1007/s13300-022-01296-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399319/
https://www.ncbi.nlm.nih.gov/pubmed/35840857
http://dx.doi.org/10.1007/s13300-022-01296-y

Ejemplares similares